Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses
T Mostafa - The journal of sexual medicine, 2008 - academic.oup.com
ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate
monophosphate (cGMP) specifically to 5′ GMP. PDE5 inhibitors were a breakthrough …
monophosphate (cGMP) specifically to 5′ GMP. PDE5 inhibitors were a breakthrough …
Useful implications of low-dose long-term use of PDE-5 inhibitors
T Mostafa - Sexual Medicine Reviews, 2016 - academic.oup.com
Abstract Introduction Phosphodiesterase type 5 (PDE-5) hydrolyzes cyclic guanylate
monophosphate (cGMP) specifically to 5′ GMP, promoting successful corporeal vascular …
monophosphate (cGMP) specifically to 5′ GMP, promoting successful corporeal vascular …
PDE5 inhibitors in non-urological conditions
C Vlachopoulos, D Terentes-Printzios… - Current …, 2009 - ingentaconnect.com
Phosphodiesterase type-5 (PDE5) inhibitors are widely used as first-line therapy for erectile
dysfunction (ED). Their efficacy and safety combined with an increasing understanding of …
dysfunction (ED). Their efficacy and safety combined with an increasing understanding of …
Non-sexual implications of phosphodiesterase type 5 inhibitors
T Mostafa - Sexual Medicine Reviews, 2017 - academic.oup.com
Abstract Introduction Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate
monophosphate specifically to 5′ guanylate monophosphate, promoting corporeal …
monophosphate specifically to 5′ guanylate monophosphate, promoting corporeal …
Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors
RA Kloner, G Comstock, LA Levine, S Tiger… - Expert Opinion on …, 2011 - Taylor & Francis
Introduction: At the present time, inhibitors of phosphodiesterase type 5 (PDE5) have Food
and Drug Administration approval only for the treatment of erectile dysfunction and …
and Drug Administration approval only for the treatment of erectile dysfunction and …
The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems
ER Schwarz, V Kapur, J Rodriguez, S Rastogi… - International journal of …, 2007 - nature.com
Abstract Phosphodiesterase-5 (PDE-5) inhibitors selectively inhibit PDE-5 enzymes that are
present in various tissues like penile tissue, platelets, vascular, and smooth muscle tissue …
present in various tissues like penile tissue, platelets, vascular, and smooth muscle tissue …
PDE5 inhibitors beyond erectile dysfunction
P Sandner, J Hütter, H Tinel, K Ziegelbauer… - International journal of …, 2007 - nature.com
Abstract The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil
are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil …
are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil …
Phosphodiesterase type 5 inhibitors: unmet needs
K Hatzimouratidis… - Current pharmaceutical …, 2009 - ingentaconnect.com
Erectile dysfunction (ED) has been revolutionized during the last two decades, as several
treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors …
treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors …
Cardiovascular effects of phosphodiesterase type 5 inhibitors
C Vlachopoulos, N Ioakeimidis… - The Journal of …, 2009 - academic.oup.com
ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-
line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an …
line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an …
Phosphodiesterase 5 inhibitors and erectile dysfunction
P Sandner, N Svenstrup, H Tinel… - Expert Opinion on …, 2008 - Taylor & Francis
Background: The introduction of phosphodiesterase 5 (PDE5) inhibitors for the treatment of
erectile dysfunction was a landmark in the therapy of this highly prevalent male disorder …
erectile dysfunction was a landmark in the therapy of this highly prevalent male disorder …